Elevation of serum copper levels in Alzheimer's disease

Neurology

Volumn 59, Issue 8, 2002, Pages 1153-1161

  Squitti, R ^a   Lupoi, D ^a   Pasqualetti, P ^a   Dal Forno, G ^c,d   Vernieri, F ^a   Chiovenda, P ^a   Rossi, L ^b   Cortesi, M ^a   Cassetta, E ^a   Rossini, P M ^a,c  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; COPPER; IRON; PEROXIDE; TRANSFERRIN;

ADULT; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN ATROPHY; BRAIN BLOOD VESSEL; COGNITIVE DEFECT; CONTROLLED STUDY; COPPER BLOOD LEVEL; DISEASE MARKER; ECHOGRAPHY; FEMALE; GENE FREQUENCY; HUMAN; IRON BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NERVE DEGENERATION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TEMPORAL LOBE; TRANSFERRIN BLOOD LEVEL;

EID: 0037159210     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.59.8.1153     Document Type: Article

References (66)

1. Rotilio G, Rossi L, de Martino A, da Costa Ferreira AM, Ciriolo MR. Free radicals, metals, ions and oxidative stress: chemical mechanisms of damage and protection in living systems. J Braz Chem Soc 1995;6:221-227.
2. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Rad Biol Med 1997;23:134-147.
3. Pratico D, Uryu K, Leight S, Trojanoswki JQ, Lee VM. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 2001;21:4183-4187.
4. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 1998;158:47-52.
5. Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 1997;94:9866-9868.
6. Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA, Smith MA. In situ catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem 2000;74:270-279.
7. Multhaup G, Schlicksupp A, Hesse L, et al. The amyloid precursor protein of Alzheimer's disease in the reduction of copper (II) to copper (I). Science 1996;271:1406-1409.
8. Huang X, Cuajungco MP, Atwood CS, et al. Cu(II) potentiation of Alzheimer Abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 1999;274:37111-37116.
9. White AR, Multhaup G, Maher F, et al. The Alzheimer's disease amyloid precursors protein modulates copper-induced toxicity and oxidative stress in primary neuronal cultures. J Neurosci 1999;19:9170-9179.
10. Cuajungco MP, Faget KY, Huang X, Tanzi RE, Bush AI. Metal chelation as therapy for Alzheimer's disease. Ann NY Acad Sci 2000;920:292-304.
11. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923.
12. Frisoni GB, Govoni S, Geroldi C, et al. Gene dose of the epsilon 4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease. Ann Neurol 1995;37:596-604.
13. Mayeux R, Saunders AM, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centres Consortium on Apolipoprotein E and Alzheimer's disease. N Engl J Med 1998;338:506-511.
14. Gonzàlez C, Martin T, Cacho J, et al. Serum zinc, copper, insulin, and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers. Eur J Clin Invest 1999;29:637-642.
15. Repetto MG, Reides CG, Evelson P, Kohan S, de Lustig ES, Llesuy SF. Peripheral markers of oxidative stress in probable Alzheimer patients. Eur J Clin Invest 1999;29:643-649.
16. Squitti R, Rossini PM, Cassetta E, et al. D-Penicillamine reduces serum oxidative stress in Alzheimer's disease patients. Eur J Clin Invest 2002;32:51-59.
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinic diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
18. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
19. Abe A, Yamashita S, Noma A. Sensitive, direct colorimetric assay for copper in serum. Clin Chem 1989;35:552-554.
20. Trotti R, Carratelli M, Barbieri M, et al. Oxidative stress and a thrombophilic condition in alcoholics without severe liver disease. Haematologica 2001;86:85-91.
21. Alberti A, Bolognini L, Macciantelli D, Carratelli M. The radical cation of N,N-diethyl-para-phenylendiamine: a possible indicator of oxidative stress in biological samples. Res Chem Intermed 2000;26:253-267.
22. Cesarone MR, Belcaro G, Carratelli M, et al. A simple test to monitor oxidative stress. Int Angiol 1999;18:127-130.
23. Rice-Evans C, Miller NJ. Total antioxidant status in plasma and body fluids. Methods Enzymol 1994;234:279-293.
24. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci 1993;84:407-412.
25. Siedel J, Wahlefeld AW, Ziegenhorn J. A new iron ferrozine reagent without deproteinization. Clin Chem 1984;30:975. Abstract.
26. Wick M, Pinggera W, Lehmann P, eds. Iron metabolism diagnosis and therapy of anemias. 3rd ed. Vienna: Springer-Verlag, 1996.
27. Lievens M, Borque de Larrea L, Rus A. Determination of transferrin without sample predilution by a turbidimetric assay on Boehringer Mannheim/Hitachi analysis systems. Lab Med 1994;18:83-90.
28. Hixson JE, Vernier DT. Restriction isotyping of human APOE by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
29. Carlesimo GA, Caltagirone C, Gainotti G. The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery. Eur Neurol 1996;36:378-384.
30. Orsini A, Chiacchio L, Cinque M, Cocchiaro C, Schiappa O, Grossi D. Effects of age, education and sex on two tests of immediate memory: a study of normal subjects from 20 to 99 years of age. Percept Mot Skills 1986;63:727-732.
31. Constans JM, Meyerhoff DJ, Gerson J, et al. H-1 MR spectroscopic imaging of white matter signal hyperintensities: Alzheimer disease and ischemic vascular dementia. Radiology 1995;197:517-523.
32. Geroldi C, Galluzzi S, Bresciani L, et al. A hierarchical scale to assess brain vascularity on CT films in dementing and non dementing cognitive impairment. J Neurol 2000;247(suppl 3): III-31. Abstract.
33. Wahlund LO, Julin P, Johansson SE, Scheltens P. Visual rating and volumetry of the medial temporal lobe of magnetic resonance imaging in dementia: a comparative study. J Neurol Neurosurg Psychiatry 2000;69:630-635.
34. Rusinek H, de Leon MJ, George AE, et al. Alzheimer disease: measuring loss of cerebral gray matter with MR imaging. Radiology 1991;178:109-114.
35. Killiany RJ, Gomez-Isla T, Moss M, et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol 2000;47:430-439.
36. Von Reutern GM, Büdingen HJ, eds. Ultrasound diagnosis in cerebrovascular disease. Stuttgart: Georg Thieme Verlag, 1989.
37. Bartels E, ed. Color-coded duplex ultrasonography of the cerebral vessels: atlas and manual. Stuttgart: Schattauer, 1999.
38. O'Leary DH, Polak F, Kronmal RA, et al. Carotid-artery intima media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Group. N Engl J Med 1999;340:14-22.
39. Aaslid R, Markwalder TM, Nornes H. Noninvasive transcranial Doppler ultrasound recording of flow velocity in basal cerebral arteries. J Neurosurg 1982;57:769-774.
40. Regland B, Lehmann W, Abedini I, et al. Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord 2001;12:408-414.
41. Ozcankaya R, Delibas N. Malondialdehyde, superoxide dismutase, melatonin, iron, copper and zinc blood concentrations in patients with Alzheimer Disease: cross-sectional study. Croat Med J 2002;43:28-32.
42. Multhaup G, Ruppert T, Schlicksupp A, et al. Copper-binding amyloid precursor protein undergoes site-specific fragmentation in the reduction of hydrogen peroxide. Biochemistry 1998;37:7224-7230.
43. Atwood CS, Moir RD, Huang X, et al. Dramatic aggregation of Alzheimer Aβ by Cu (II) is induced by conditions representing physiological acidosis. J Biol Chem 1998;273:12817-12826.
44. Hartter DE, Barnea A. Brain tissue accumulates copper by two ligand-dependent saturable processes. A high affinity, low capacity and a low affinity, high capacity process. J Biol Chem 1988;263:799-805.
45. Cherny RA, Barnham KJ, Lynch T, et al. Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's diseases. J Struct Biol 2000;130:209-216.
46. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001;30:665-676.
47. Goodman Y, Bruce AJ, Cheng B, Mattson MP. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid B peptide toxicity in hippocampal neurons. J Neurochem 1996;66:1836-1844.
48. Ramassamy C, Averill D, Beffert U, et al. Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Rad Biol Med 1999;27:544-553.
49. Selhub J, Bagley LC, Miller J, Rosemberg IH. B vitamins, homocysteine, and neurocognitive function in the elderly. Am J Clin Nutr 2000;71:614S-620S.
50. Linder MC, Hazegh-Azam M. Copper biochemistry and molecular biology. Am J Clin Nutr 1996;63:797S-811S.
51. Cuajungco MP, Goldstein LE, Nunomura A, et al. Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of the Aβ by zinc. J Biol Chem 2000;275:19439-19442.
52. Kisilevsky R. Inflammation-associated amyloidogenesis. Lessons for Alzheimer's amyloidogenesis. Mol Neurobiol 1994;8:65-66.
53. Eberling JL, Jagust WJ, Reed BR, Baker MG. Reduced temporal lobe blood flow in Alzheimer's disease. Neurobiol Aging 1992;13:483-491.
54. Nourhashèmi F, Gillette-Guyonnet S, Andrieu S, et al. Alzheimer disease: protective factors. Am J Clin Nutr 2000;71:643S-649S.
55. Wang HX, Wahlin A, Basun H, Fastbom J, Winblad B, Fratiglioni L. Vitamin B (12) and folate in relation to the development of Alzheimer's disease. Neurology 2001;56:1188-1194.
56. 12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998;55:1449-1455.
57. 12 deficiency. Age Ageing 1994;23:334-337.
58. Sano M, Ernesto C, Thomas RG, et al. A controlled clinical trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997;336:1216-1222.
59. Corbo RM, Scacchi R, Mureddu L, Mulas G, Alfano G. Apolipoprotein E polymorphism in Italy investigated in native plasma by a simple polyacrylamide gel isoelectric focusing technique. Comparison with frequency data of other European populations. Ann Hum Genet 1995;59:197-209.
60. Akil M, Brewer GJ. Psychiatric and behavioral abnormalities in Wilson's disease. Adv Neurol 1995;65:171-178.
61. Rathbun JK. Neuropsychological aspects of Wilson's disease. Int J Neurosci 1996;85:221-229.
62. Schiefermeier M, Kollegger H, Madl C, et al. The impact of apolipoprotein E genotypes on age at onset of symptoms and phenotypic expression in Wilson's disease. Brain 2000;123:585-590.
63. Moir RD, Atwood CS, Romano DM, et al. Differential effects of apolipoprotein E isoforms on metal-induced aggregation of Aβ using physiological concentrations. Biochemistry 1999;38:4595-4603.
64. Tamaoka A, Miyatake F, Matsuno S, et al. Apolipoprotein E allele-dependent antioxidant activity in brains with Alzheimer's disease. Neurology 2000;54:2319-2321.
65. Moir RD, Atwood CS, Huang X, Tanzi RE, Bush AI. Mounting evidence for the involvement of zinc and copper in Alzheimer's disease. Eur J Clin Invest 1999;29:569-570.
66. Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G. Oxidative stress in Alzheimer's disease. Biochim Biophys Acta 2000;1502:139-144.